Navigation Links
New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
Date:12/10/2007

ressure.

LEVITRA is not recommended for patients with uncontrolled hypertension (>170/110 mmHg).

In men for whom sexual activity is not recommended because of their underlying cardiovascular status, any treatment for erectile dysfunction, including LEVITRA, generally should not be used.

In patients taking certain CYP3A4 inhibitors (eg, ritonavir, indinavir, saquinavir, atazanavir, ketoconazole, itraconazole, erythromycin, and clarithromycin), lower doses of LEVITRA are recommended, and time between doses of LEVITRA may need to be extended. See prescribing information for LEVITRA for dosing guidance.

In clinical trials, the most commonly reported adverse events with LEVITRA were headache, flushing, and rhinitis. Adverse events were generally transient.

Nonarteritic anterior ischemic optic neuropathy (NAION) has been reported rarely postmarketing in temporal relationship with the use of PDE5 inhibitors, including LEVITRA. Sudden loss of hearing, sometimes with tinnitus and dizziness, also has been reported rarely in temporal association with the use of PDE5 inhibitors, including LEVITRA. It is not possible to determine if these events are related to PDE5 inhibitors or to other factors. Physicians should advise patients to stop use of PDE5 inhibitors, including LEVITRA, and seek prompt medical attention in the event of sudden loss of vision or hearing.

The recommended starting dose of LEVITRA is 10 mg. Titrate up to 20 mg or down to 5 mg based on efficacy and side effects.
The maximum recommended dosing frequency is once daily.

LEVITRA is available in 2.5-mg, 5-mg, 10-mg and 20-mg tablets.

For Prescribing Information please visit http://www.levitra.com.

About GlaxoSmithKline

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling peop
'/>"/>

SOURCE Schering-Plough
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Germany , March 5, 2015 /PRNewswire-USNewswire/ ... CureVac today announced that the foundation has made ... in CureVac, a leading clinical-stage biopharmaceutical company specializing ... agreement, the foundation will also provide separate funding ... on CureVac,s proprietary messenger RNA (mRNA) platform. In ...
(Date:3/5/2015)... , March 5, 2015 CANTEL MEDICAL CORP. ... its second quarter ended January 31, 2015 on Thursday, March ... to discuss the results at 11:00 AM ET. ... approximately 5 to 10 minutes before the beginning of the ... of the call will be available from Thursday, March 12, ...
(Date:3/5/2015)... , March 5, 2015   AMC ... management solutions recognized for improving the effectiveness and ... that Robert Anazagasty and Jared ... serve as Vice President, Strategic Client Development, and ... These additions support AMC Health,s commitment to accelerating ...
Breaking Medicine Technology:The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 3
(Date:3/6/2015)... March 06, 2015 Medical Products, Inc., ... an agreement with GE Healthcare to become an authorized ... United States. , MPI has 31 years in distribution ... Healthcare. , With this agreement, MPI will have the ... the healthcare industry. , MPI has always strived ...
(Date:3/5/2015)... The global digital PCR (dPCR) and qPCR market ... 7.8% from 2014 to 2019. , The global digital PCR (dPCR) ... 7.8% from 2014 to 2019. Although the mature markets such as ... digital PCR (dPCR) and qPCR market the Asia-Pacific region is expected ... period. The growth of the digital PCR (dPCR) and qPCR market ...
(Date:3/5/2015)... York, NY (PRWEB) March 05, 2015 ... move forward in a Pennsylvania mass tort litigation ... Pleas, where a jury has begun hearing testimony ... that the atypical antipsychotic medication can cause gynecomastia, ... the case in question was filed on behalf ...
(Date:3/5/2015)... March 05, 2015 The Maricopa ... of income to the Arizona economy each year, according ... Demonstrating the Economic Value of Maricopa County Community College ... the Maricopa district in fiscal year 2013-2014. , ... International (EMSI), an organization that specializes in providing ...
(Date:3/5/2015)... At the 7th Annual Mississippi Addiction ... treatment met today in Jackson, Mississippi to listen to ... the numerous respected speakers will be William S. ... that pain medications have had in today’s opiate overdose ... "It is hard to believe that much of the ...
Breaking Medicine News(10 mins):Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 2Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 3Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3
... shingles cases, expert says , , THURSDAY, May 15 ... should be vaccinated against shingles, a condition that can ... Control and Prevention recommended on Thursday. , This new ... after the ZOSTAVAX vaccine was approved by the U.S. ...
... Despite daily use of doctor-recommended proton pump inhibitors ... nearly 40 percent of patients who take them ... of GERD symptoms, such as acid regurgitation and ... of GERD sufferers to use over-the-counter (OTC) remedies, ...
... Pharmaceutical research and,development (R&D) is a complex endeavor. It ... of investment to turn a molecule into a medicine ... market, is filled,with challenges. For every 10 compounds that ... market. "From Molecule to Medicine," is an,award-winning movie created ...
... May 15 Sanofi-aventis announced that,the U.S. Court of ... 2007 decision by the U.S. District Court for the ... suit,against Amphastar and Teva., As a result of ... deemed to be unenforceable., Sanofi-aventis is considering all ...
... 15 American Diabetes,Wholesale (ADW), a discount provider of ... on the Performics network. ADW hopes to,expand its online ... will pay its affiliate partners a percentage of every ... sales. "We see our affiliate,program as a great way ...
... of how cancer cells spread have led to a ... stem cell characteristics, offering potentially major implications for regenerative ... acquire the ability to migrate through the body by ... embryo stage, as the lab of Whitehead Member Robert ...
Cached Medicine News:Health News:CDC Recommends Shingles Vaccine for Those Over 60 2Health News:CDC Recommends Shingles Vaccine for Those Over 60 3Health News:Nearly 40 percent of GERD patients taking PPIs experience recurring symptoms 2Health News:Nearly 40 percent of GERD patients taking PPIs experience recurring symptoms 3Health News:District Court Decision Affirmed in U.S. Lovenox(R) (enoxaparin sodium) Patent Infringement Case 2Health News:American Diabetes Wholesale Launches Affiliate Program 2Health News:Embryonic pathway delivers stem cell traits 2Health News:Embryonic pathway delivers stem cell traits 3Health News:Embryonic pathway delivers stem cell traits 4
Wire mesh braided design with a platinum core....
... Finnpipette Focus multichannel pipettes ... of reagents into microplates, ... 0.1-10 l volumes. The ... Finnpipette Focus multichannels, combined ...
... The Finnpipette Digital Multichannel, ... even lighter work of routine ... all these advanced features: Soft-touch ... micro volume pipetting (0.5-10ul models), ...
... and Benefits: 1-12channel pipette This ... product number, created to easily ... showing no availability yet, please ... number (Z37,173-4) or contact customer ...
Medicine Products: